Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE: Dalteparin for VTE prophylaxis in brain tumor patients
NCT00135876Phase 3Completed
- Sponsor
- Ontario Clinical Oncology Group
- Start
- Oct 2002
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 3 trial of dalteparin in venous thromboembolism (VTE), sponsored by Ontario Clinical Oncology Group. Started Oct 2002; status: completed.
02
Drugs
dalteparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00135876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135876.